FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor

被引:89
作者
Cheung, NKV
Sowers, R
Vickers, AJ
Cheung, IY
Kushner, BH
Gorlick, R
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Albert Einstein Coll Med, Childrens Hosp Montefiore, Dept Pediat, New York, NY USA
关键词
D O I
10.1200/JCO.2005.04.6011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Anti-GD2 murine IgG3 antibody 3F8 kills neuroblastoma cells by antibody-dependent cell-mediated cytotoxicity (ADCC). Granulocyte macrophage colony-stimulating factor (GM-CSF) enhances phagocyte-mediated ADCC. The differential affinity of the human FCGR polymorphic alleles for 3F8 may influence the effectiveness of antibody immunotherapy. Patients and Methods The entire cohort of high risk neuroblastoma patients (N = 136) treated on protocol using 3F8 and GM-CSF were the subjects of this analysis. Tumor response was measured by standard clinical tools plus sensitive molecular monitoring using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Polymorphic alleles of FCGR2A and FCGR3A were determined by PCR plus direct sequencing using genomic DNA samples obtained from marrow or blood of patients. Results FCGR2A (R/R) genotype correlated with progression-free survival for the entire cohort (P = .049) and for the subset of patients with no history of prior relapse (P = .023). FCGR2A (R/R) also correlated with marrow remission 2.5 months after treatment initiation: by histology (P = .021 and P = .036, for the entire cohort and the subset, respectively) and by qRT-PCR (P = .052 and P = .033, respectively). Conclusion The favorable outcome associated with FCGR2A (R/R) genotype is consistent with the proposed role of FCGR2A and phagocyte-mediated ADCC in 3F8 plus GM-CSF immunotherapy.
引用
收藏
页码:2885 / 2890
页数:6
相关论文
共 48 条
[41]   A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcγRIIb alters receptor expression and associates with autoimmunity.: I.: Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus [J].
Su, KH ;
Wu, JM ;
Edberg, JC ;
Li, XL ;
Ferguson, P ;
Cooper, GS ;
Langefeld, CD ;
Kimberly, RP .
JOURNAL OF IMMUNOLOGY, 2004, 172 (11) :7186-7191
[42]   POLYMORPHISM IN MITOGENIC EFFECT OF IGG1 MONOCLONAL-ANTIBODIES AGAINST T3 ANTIGEN ON HUMAN T-CELLS [J].
TAX, WJM ;
WILLEMS, HW ;
REEKERS, PPM ;
CAPEL, PJA ;
KOENE, RAP .
NATURE, 1983, 304 (5925) :445-447
[43]   Role of polymorphic Fc receptor Fc gamma RIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31) [J].
Tax, WJM ;
Tamboer, WPM ;
Jacobs, CWM ;
Frenken, LAM ;
Koene, RAP .
TRANSPLANTATION, 1997, 63 (01) :106-112
[44]   Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils [J].
van der Kolk, LE ;
de Haas, M ;
Grillo-López, AJ ;
Baars, JW ;
van Oers, MHJ .
LEUKEMIA, 2002, 16 (04) :693-699
[45]   FcγR polymorphisms:: Implications for function, disease susceptibility and immunotherapy [J].
van Sorge, NM ;
van der Pol, WL ;
van de Winkel, JGJ .
TISSUE ANTIGENS, 2003, 61 (03) :189-202
[46]   IgG Fc-receptor polymorphisms in Guillain-Barre syndrome [J].
Vedeler, CA ;
Raknes, G ;
Myhr, KM ;
Nyland, H .
NEUROLOGY, 2000, 55 (05) :705-707
[47]   FC-RECEPTOR FOR MOUSE IGG1 (FC-GAMMA-RII) AND ANTIBODY-MEDIATED CELL CLEARANCE IN PATIENTS TREATED WITH LEU2A ANTIBODY [J].
WEE, SL ;
COLVIN, RB ;
PHELAN, JM ;
PREFFER, FI ;
REICHERT, TA ;
BERD, D ;
COSIMI, AB .
TRANSPLANTATION, 1989, 48 (06) :1012-1017
[48]   Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma [J].
Weng, WK ;
Levy, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3940-3947